Buscar
ARS Pharmaceuticals Inc
SPRYAñadir a la lista de seguimiento
7.655USD
-0.285-3.59%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
760.07MCap. mercado
PérdidaP/E TTM
Más Datos de ARS Pharmaceuticals Inc Compañía
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Información de ARS Pharmaceuticals Inc
Símbolo de cotizaciónSPRY
Nombre de la empresaARS Pharmaceuticals Inc
Fecha de salida a bolsaDec 04, 2020
Director ejecutivoLowenthal (Richard E)
Número de empleados155
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 04
Dirección11682 El Camino Real, Suite 300
CiudadSAN DIEGO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92130
Teléfono18587719307
Sitio Webhttps://ars-pharma.com/
Símbolo de cotizaciónSPRY
Fecha de salida a bolsaDec 04, 2020
Director ejecutivoLowenthal (Richard E)
Ejecutivos de ARS Pharmaceuticals Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.44%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Dr. Peter A. Thompson, M.D.
Dr. Peter A. Thompson, M.D.
Independent Director
Independent Director
--
--
Mr. Saqib Islam, J.D.
Mr. Saqib Islam, J.D.
Independent Director
Independent Director
--
--
Ms. Kathleen D. (Kathy) Scott
Ms. Kathleen D. (Kathy) Scott
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Eric Karas
Mr. Eric Karas
Chief Commercial Officer
Chief Commercial Officer
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard E. Lowenthal
Mr. Richard E. Lowenthal
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
10.06M
+32.09%
Dr. Sarina Tanimoto, M.D.
Dr. Sarina Tanimoto, M.D.
Chief Medical Officer
Chief Medical Officer
1.25M
-266.69%
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Mr. Alexander A. Fitzpatrick, Esq., J.D.
Secretary and Chief Legal Officer
Secretary and Chief Legal Officer
86.26K
-3.44%
Mr. Michael Kelly
Mr. Michael Kelly
Independent Director
Independent Director
83.22K
--
Mr. Brian T. Dorsey
Mr. Brian T. Dorsey
Chief Operating Officer
Chief Operating Officer
7.65K
--
Dr. Laura K. Shawver, Ph.D.
Dr. Laura K. Shawver, Ph.D.
Director
Director
--
--
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de abr
Divisa: USDActualizado: lun., 6 de abr
FY2025
La empresa aún no ha revelado los datos relevantes.
Por regiónUSD
Nombre
Ganancia
Proporción
United States
72.19M
85.66%
Rest of the world
12.09M
14.34%
Por negocio
Por región
La empresa aún no ha revelado los datos relevantes.
Estadísticas de accionistas
Actualizado: dom., 10 de may
Actualizado: dom., 10 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
RA Capital Management, LP
10.94%
Lowenthal (Richard E)
10.13%
OrbiMed Advisors, LLC
8.35%
Deerfield Management Company, L.P.
7.56%
Rubric Capital Management LP
6.24%
Otro
56.79%
Accionistas
Accionistas
Proporción
RA Capital Management, LP
10.94%
Lowenthal (Richard E)
10.13%
OrbiMed Advisors, LLC
8.35%
Deerfield Management Company, L.P.
7.56%
Rubric Capital Management LP
6.24%
Otro
56.79%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
29.81%
Investment Advisor
19.03%
Investment Advisor/Hedge Fund
16.80%
Venture Capital
15.02%
Individual Investor
11.79%
Private Equity
8.35%
Corporation
4.51%
Research Firm
3.84%
Bank and Trust
0.67%
Participación institucional
Actualizado: mié., 1 de abr
Actualizado: mié., 1 de abr
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2026Q1
412
96.79M
97.47%
-8.90M
2025Q4
397
88.21M
89.24%
-10.35M
2025Q3
381
87.74M
88.78%
-2.41M
2025Q2
367
96.00M
97.76%
-11.66M
2025Q1
380
100.63M
102.48%
-12.75M
2024Q4
345
96.62M
99.42%
-14.07M
2024Q3
320
88.19M
90.90%
-18.52M
2024Q2
291
87.17M
89.94%
-20.35M
2024Q1
289
89.45M
92.60%
-16.44M
2023Q4
280
92.18M
96.08%
-6.49M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
RA Capital Management, LP
10.86M
10.94%
--
--
Dec 31, 2025
Lowenthal (Richard E)
6.83M
6.88%
-1.14M
-14.34%
Mar 31, 2025
OrbiMed Advisors, LLC
8.29M
8.35%
--
--
Dec 31, 2025
Deerfield Management Company, L.P.
7.50M
7.56%
--
--
Dec 31, 2025
Rubric Capital Management LP
6.20M
6.24%
+1.70M
+37.78%
Dec 31, 2025
Millennium Management LLC
5.39M
5.43%
+2.22M
+70.16%
Mar 17, 2026
BlackRock Institutional Trust Company, N.A.
4.53M
4.56%
+182.14K
+4.19%
Dec 31, 2025
Pratik Shah Living Trust
4.82M
4.86%
--
--
Mar 31, 2025
abrdn Inc.
3.56M
3.58%
+459.03K
+14.82%
Dec 31, 2025
SR One Capital Management, LP
4.01M
4.04%
--
--
Dec 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de dic
Actualizado: sáb., 6 de dic
Nombre
Proporción
ALPS Medical Breakthroughs ETF
0.38%
State Street SPDR S&P Biotech ETF
0.32%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
0.16%
ProShares Ultra Nasdaq Biotechnology
0.11%
Principal U.S. Small-Cap ETF
0.09%
Invesco Nasdaq Biotechnology ETF
0.08%
iShares US Small-Cap Equity Factor ETF
0.05%
iShares Biotechnology ETF
0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.04%
Ver más
ALPS Medical Breakthroughs ETF
Proporción0.38%
State Street SPDR S&P Biotech ETF
Proporción0.32%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.16%
VictoryShares US Small Mid Cap Value Momentum ETF
Proporción0.16%
ProShares Ultra Nasdaq Biotechnology
Proporción0.11%
Principal U.S. Small-Cap ETF
Proporción0.09%
Invesco Nasdaq Biotechnology ETF
Proporción0.08%
iShares US Small-Cap Equity Factor ETF
Proporción0.05%
iShares Biotechnology ETF
Proporción0.05%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporción0.04%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
Fecha
Fecha ex-dividendo
Tipo
Relación
Sin datos
